You are here
ANALYSIS: Biden's vaccine waiver "pretty marginal" for increasing supply. Germany opposes
Primary tabs
“I genuinely think it’s pretty marginal,” said Rachel Silverman, a policy analyst with the Center for Global Development, a nonprofit think tank, who has warned that an intellectual property waiver raises complicated questions and won’t immediately boost supply to virus-ravaged countries such as India and Brazil. “I think it will not have disastrous effects. I don’t think it will do much to speed production.”
Still, Silverman praised President Biden’s willingness to take “bold and unprecedented action” to prioritize the global virus fight “above some of our more conventional foreign policy interests” and signal to developing countries that “we are not indifferent, that we are listening, and that we care about vaccinating them.”
Others suggested that the United States putting its muscle behind the proposal brings pressure on all players, including vaccine makers and other developed countries, to find other, more practical ways to speed vaccines to the developing world, especially amid the growing outcry over the gap between rich and poor countries. The desperation in India, where only 2.2 percent of the population is fully vaccinated as hospitals run out of oxygen, compared with almost 33 percent of the U.S. population being fully vaccinated, has underscored the issue.
The head of the World Trade Organization said Thursday that she would press member countries to reach an agreement on the waiver petition no later than December, setting Dec. 3 as the target for a final agreement. ...
ALSO SEE: Germany resists calls to waive patents on Covid-19 vaccines
AND: Analysis: U.S. move to loosen vaccine patents will draw drug companies to bargain _Reuters
Recent Comments